Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Most Pharmacists Believe Generics Equal Brand Name Drugs, AARP Study Says

This article was originally published in The Pink Sheet Daily

Executive Summary

About two-thirds of pharmacists say they agree that generic drugs “must be therapeutically equivalent” with brand name drugs. AARP’s recent survey of physicians found only 40% of physicians agreed with the same statement.

You may also be interested in...



Purdue Signs On To Market Labopharm's Once-Daily Tramadol

Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.

Merck KGaA Boosts U.S. Generic Market Presence With Genpharm Expansion

Genpharm opens office in New York headed by former Able CEO Robert Mauro.

PhRMA DTC Principles Call For End Of Reminder Ads

Independent review panel will be established to handle complaints about pharmaceutical advertising.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel